Insights
Insights From Our Experts
Articles
The Art of Simplifying Pharmacovigilance – Part I: Connecting the Dots
The Art of Simplifying Pharmacovigilance – Part I: Connecting the Dots In the intricate realm of pharmacovigilance, there is an art — a delicate dance of connecting the dots. Like a skilled painter, vigilant professionals adeptly…
Commercial Key Success Factors (KSFs) for Global Drug Development Programs
Key Contributor: Robin Arnold, Executive Vice President Discover the essential commercial key success Factors (KSFs) that drive triumph in global drug development programs. In an era of diverse regulatory perspectives and reimbursement complexities, biotech companies face higher…
The Role of RWE in Expediting the Drug Approval Process
Key Contributors: Lydia Edison (Project Manager), Rohit Mandlik (Project Manager), Rohit Dang (Engagement Manager), Mahendra Rai (Senior Director) The role of real-world evidence (RWE) in expediting the drug approval process. RWE refers to the use of…
Specialty Pharmacies are Ready for the Biosimilar Boom. Are you?
The pharmacy benefit biologic market is primed for disruption, with Specialty Pharmacies (SPs) eagerly awaiting the pending market shift. While biosimilars have been available for nearly a decade in the United States, this year will be…
Position Your Future-Facing Strategy on Digital Therapeutics (DTx) in China
How can DTx resonate with current portfolios and capture incoming opportunities? Key Contributors: Robin Arnold, Executive Vice President; Jerry Song, Associate Principal; Qiwei (Alex) Li, Consultant The article discusses the potential of digital therapeutics (DTx) in China’s healthcare…
Overcoming the Commercialization Challenges of Personalized Cancer Immunotherapies
Personalized cancer immunotherapies are emerging as a revolutionary approach to cancer treatment, aiming to provide individualized therapies based on a patient’s specific genetic makeup. The FDA has not yet approved any personalized cancer immunotherapies, creating an…
A Comparison of Existing Real World Evidence (RWE) Guidelines
Key Contributors: Neel Patel, Associate Consultant- HEOR, APAC and Rajanikanth Manupati, Associate Consultant- HEOR, APAC In the fast-paced world of healthcare, where the development and approval of new therapies can take over a decade, the need…
Innovative Approaches to 340B Claims Data Identification
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research…
Key Considerations When Operationalizing Revenue Management
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’…
Understanding the Inflation Reduction Act: Drug Price Negotiation
In this second of a series, we explore the details known so far about Medicare drug price negotiation resulting from the implementation of the Inflation Reduction Act. The Centers for Medicare and Medicaid Services (CMS) has…